Literature DB >> 2155785

Activity and interleukin 1 responsiveness of SV40 enhancer motifs in a rodent immature T cell line.

E Espel1, C Fromental, P Reichenbach, M Nabholz.   

Abstract

We have analysed the enhancer activity and the interleukin 1 (IL1) responsiveness of individual motifs of the SV40 enhancer in an immature rodent T cell line, PC60. Transient transfection assays showed that tetramers of GT-I plus GT-IIC motifs, the TC-II or the P motif have significant enhancer activity in PC60, while neither Octamer nor SphI+II motifs have a detectable effect on promoter strength. Two motifs, TC-II and P, strongly respond to stimulation by IL1. DNase I and methylation protection experiments with nuclear extracts show specific footprints in the TC-II region of the SV40 enhancer. Exposure of PC60 cells to IL1 increases their intensity. The TC-II sequence forms several complexes detected in band shift assays. The molecules involved all have similar sequence specificity as NF-kappa B. Surprisingly, band shifts with extracts from control or IL1 treated cells differ only slightly. However, if GTP is added to the binding reactions the intensity of bands formed by extracts from control cells is strongly reduced, whereas extracts from IL1 treated cells form a single retarded complex that co-migrates with NF-kappa B from a pre-B cell line. The results suggest that in PC60 IL1 induces NF-kappa B activity by activating molecules that are already in the nucleus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155785      PMCID: PMC551755          DOI: 10.1002/j.1460-2075.1990.tb08191.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  71 in total

1.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

2.  The role of the kappa enhancer and its binding factor NF-kappa B in the developmental regulation of kappa gene transcription.

Authors:  M L Atchison; R P Perry
Journal:  Cell       Date:  1987-01-16       Impact factor: 41.582

3.  Binding, internalization, and intracellular localization of interleukin-1 beta in human diploid fibroblasts.

Authors:  E E Qwarnstrom; R C Page; S Gillis; S K Dower
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

4.  Interleukin 1 modulates messenger RNA levels of lymphokines and of other molecules associated with T cell activation in the T cell lymphoma LBRM33-1A5.

Authors:  H Hagiwara; H J Huang; N Arai; L A Herzenberg; K Arai; A Zlotnik
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

Review 5.  Trans-acting protein factors and the regulation of eukaryotic transcription: lessons from studies on DNA tumor viruses.

Authors:  N C Jones; P W Rigby; E B Ziff
Journal:  Genes Dev       Date:  1988-03       Impact factor: 11.361

6.  Cell-type specific protein binding to the enhancer of simian virus 40 in nuclear extracts.

Authors:  I Davidson; C Fromental; P Augereau; A Wildeman; M Zenke; P Chambon
Journal:  Nature       Date:  1986 Oct 9-15       Impact factor: 49.962

7.  Transmembrane signaling during interleukin 1-dependent T cell activation. Interactions of signal 1- and signal 2-type mediators with the phosphoinositide-dependent signal transduction mechanism.

Authors:  R T Abraham; S N Ho; T J Barna; D J McKean
Journal:  J Biol Chem       Date:  1987-02-25       Impact factor: 5.157

8.  Induction of c-fos and c-myc expression in T lymphocytes after treatment with recombinant interleukin 1-alpha.

Authors:  E J Kovacs; J J Oppenheim; H A Young
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

9.  The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV.

Authors:  E Böhnlein; J W Lowenthal; M Siekevitz; D W Ballard; B R Franza; W C Greene
Journal:  Cell       Date:  1988-06-03       Impact factor: 41.582

10.  Interleukin-1 stimulates diacylglycerol production in T lymphocytes by a novel mechanism.

Authors:  P M Rosoff; N Savage; C A Dinarello
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

View more
  7 in total

1.  Characterization of a new tissue-specific transcription factor binding to the simian virus 40 enhancer TC-II (NF-kappa B) element.

Authors:  A L Lattion; E Espel; P Reichenbach; C Fromental; P Bucher; A Israël; P Baeuerle; N R Rice; M Nabholz
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

2.  Enhancement of NF-kappaB activity by resveratrol in cytokine-exposed mesangial cells.

Authors:  Y Uchida; H Yamazaki; S Watanabe; K Hayakawa; Y Meng; N Hiramatsu; A Kasai; K Yamauchi; J Yao; M Kitamura
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

3.  Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1.

Authors:  S Quinones; G Buttice; M Kurkinen
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

4.  Nuclear factor of activated T-cells (NFAT) plays a role in SV40 infection.

Authors:  Kate Manley; Bethany A O'Hara; Walter J Atwood
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

5.  Requirements for the induction of the interleukin-2 receptor complex in a human pre-T-cell line.

Authors:  P D Salvati; S E Peroni; P R Ranford; U R Kees
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

6.  A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1 alpha induced, NF kappa B mediated trans-activation of the angiotensinogen gene acute-phase response element.

Authors:  A R Brasier; D Ron; J E Tate; J F Habener
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

7.  Elf-1 contributes to the function of the complex interleukin (IL)-2-responsive enhancer in the mouse IL-2 receptor alpha gene.

Authors:  I Serdobova; M Pla; P Reichenbach; P Sperisen; J Ghysdael; A Wilson; J Freeman; M Nabholz
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.